Therefore, combination immunotherapy targeting TSP50, SERCA2 and IL-8 molecules would be a valuable effective therapy for inhibiting colorectal carcinoma initiation, proliferation and metastasis. The gene discussed is ATP2A2; the disease is colorectal carcinoma.